Sunshine Biopharma

Sunshine Biopharma is a pharmaceutical company that develops and commercializes generic and specialty prescription drugs in Canada and the United States, alongside an early-stage research pipeline in antivirals and oncology. Its research programs include SBFM-PL4, a protease inhibitor being developed for SARS coronavirus infections, and K1.1 mRNA, a lipid nanoparticle candidate for liver cancer. The commercial side of the business markets a portfolio of generic prescription medications spanning osteoporosis, cardiovascular, hypertension, anti-inflammatory, diabetes, oncology, gastroenterology, dermatology, women's health and central nervous system indications, and the company also sells consumer health products including the Essential 9 amino-acid capsules and Calcium-Vitamin D supplements. The company is headquartered in Fort Lauderdale, Florida and trades on the Nasdaq Capital Market, where it has undertaken two reverse stock splits within a year — a 1-for-10 split effective June 1, 2026, and a written-consent authorization on September 15, 2026 for a further split of up to 1-for-20 — in both cases to maintain compliance with the exchange's minimum bid price requirement.